[1] Wang Z, Wu Z, Liu Y, et al. New development in CAR-T cell therapy[J]. Journal of Hematology&Oncology, 2017, 10(1):53.
[2] Rosenberg S A, Lotze M T, Muul L M, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer[J]. New England Journal of Medicine, 1985, 313(1):1485-1492.
[3] Srivastava S, Riddell S R. Engineering CAR-T cells:Design concepts[J]. Trends in Immunology, 2015, 36(8):494-502.
[4] Kakarla S, Gottschalk S. CAR T cells for solid tumors:Armed and ready to go[J]. Cancer Journal, 2014, 20(2):151-155.
[5] Jones B S, Lamb L S, Goldman F, et al. Improving the safety of cell therapy products by suicide gene transfer[J]. Frontiers in Pharmacology, 2014, 5(524):254.
[6] Seton-Rogers S. Immunotherapy:Two antigens are better than one[J]. Nature Reviews Cancer, 2016, 16(3):128-129.
[7] Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20(24):6418-6428.
[8] Wilkie S, Picco G, Foster J, et al. Retargeting of human T cells to tumor-associated MUC1:The evolution of a chimeric antigen receptor[J]. The Journal of Immunology, 2008, 180(7):4901-4909.
[9] Posey A D, Schwab R D, Boesteanu A C, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma[J]. Immunity, 2016, 44(6):1444-1454. |
[1] |
. [J]. Science & Technology Review, 2017, 35(9): 1-1. |
[2] |
. [J]. Science & Technology Review, 2017, 35(9): 7-7. |
[3] |
. [J]. Science & Technology Review, 2017, 35(9): 11-11. |
[4] |
JIANG Dan, LIU Yu, DING Jian, MA Minmin, Meng Ju, HUANG Yaojiang. The development of a Melanogrammus aeglefinus DNA standard sample[J]. Science & Technology Review, 2017, 35(9): 100-106. |
[5] |
. [J]. Science & Technology Review, 2017, 35(9): 109-109. |
[6] |
. [J]. Science & Technology Review, 2017, 35(9): 0-0. |
|
|
|